SPX3,845.08+13.69 0.36%
DIA310.41+0.70 0.23%
IXIC11,361.85+39.61 0.35%

BRIEF-Abbvie Presents Investigational Navitoclax Preliminary Data In JAK Inhibitor Naïve Myelofibrosis Patients

reuters.com · 06/10/2022 03:18
BRIEF-Abbvie Presents Investigational Navitoclax Preliminary Data In JAK Inhibitor Naïve Myelofibrosis Patients

- Abbvie Inc ABBV:

  • ABBVIE PRESENTS INVESTIGATIONAL NAVITOCLAX PRELIMINARY DATA IN JAK INHIBITOR NAÏVE MYELOFIBROSIS PATIENTS

  • ABBVIE - PRELIMINARY SAFETY ANALYSIS IDENTIFIED NO NEW SAFETY SIGNALS; THIRTY-ONE (97 PERCENT) PATIENTS REPORTED ONE OR MORE ADVERSE EVENT

Source text for Eikon: ID:nPn7LxTTga

Further company coverage: ABBV


((Reuters.Briefs@thomsonreuters.com;))